Comparison of highly pure rAAV9 vector stocks produced in suspension by PEI transfection or HSV infection reveals striking quantitative and qualitative differences

Recent clinical successes have propelled recombinant adeno-associated virus vectors (rAAV) to the center stage for human gene therapy applications. However, the exploding demand for high titers of highly pure rAAV vectors for clinical applications and market needs remains hindered by challenges met...

Descripción completa

Detalles Bibliográficos
Autores principales: Trivedi, Prasad D., Yu, Chenghui, Chaudhuri, Payel, Johnson, Evan J., Caton, Tina, Adamson, Laura, Byrne, Barry J., Paulk, Nicole K., Clément, Nathalie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760416/
https://www.ncbi.nlm.nih.gov/pubmed/35071688
http://dx.doi.org/10.1016/j.omtm.2021.12.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760416/
https://www.ncbi.nlm.nih.gov/pubmed/35071688
http://dx.doi.org/10.1016/j.omtm.2021.12.006

Ejemplares similares